Sunday, January 30

7:00 p.m.-8:00 p.m.  **Keynote Session**  
*Randle Ballroom*

*Inflammation and cancer: Interweaving microRNA free radicals, inflammatory cytokines, and p53 networks*  
Curtis C. Harris, National Cancer Institute, Bethesda, MD

8:00 p.m.-9:30 p.m.  **Networking Reception**  
*Spa Pool Deck*

Monday, January 31

7:00 a.m.-8:00 a.m.  **Continental Breakfast**  
*Randle Foyer Terrace*

8:00 a.m.-10:00 a.m.  **Session 1: Infection, Inflammation, and Cancer**  
*Chairperson: James G. Fox, Massachusetts Institute of Technology, Cambridge, MA*  
*Randle Ballroom*

*Helicobacter-associated chronic inflammation and gastrointestinal cancers*  
James G. Fox

*Gastric cancer: An infectious disease*  
Pelayo Correa, Vanderbilt University Medical Center, Nashville, TN

*Hepatitis B viral mutations and inflammation in liver cancer*  
John D. Groopman, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD

*Mechanisms of inflammasome activation in asbestos-associated mesothelioma*  
Brooke T. Mossman, University of Vermont College of Medicine, Burlington, VT
10:00 a.m.-10:30 a.m.  Break
   Randle Foyer

10:30 a.m.-11:30 p.m.  Minisymposium I
   Proffered presentations from selected abstracts
   Randle Ballroom

Inflammation in TGFβ-mediated carcinogenesis
B.R. Achyut, National Cancer Institute, Bethesda, MD

Tumor-recruited inflammatory neutrophils and their TIMP-free MMP-9 determine coordinately the levels of tumor angiogenesis and malignant cell dissemination
Elena I. Deryugina, The Scripps Research Institute, La Jolla, CA

Signal integration from PI 3-kinases and phospholipase D regulates proinflammatory NADPH oxidase activity and extracellular reactive oxygen species production
Christian D. Ellson, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

Oxidative stress as a target for drug development in prostate cancer
Athanasios Paschos, McMaster University and Juravinski Cancer Center, Hamilton, ON, Canada

11:30 a.m.-1:30 p.m.  Lunch on own
   Optional Professional Advancement Session in Manchester Ballroom

1:30 p.m.-3:30 p.m.  Session 2: Chemical Mediators of Inflammation I
   Chairperson: David A. Wink, National Cancer Institute, Bethesda, MD
   Randle Ballroom

Different levels of nitric oxide determine distinct pathways that lead to promotion or inhibition of cancer progression
David A. Wink

Macrophage pathways for oxidative damage in humans
Jay W. Heinecke, University of Washington School of Medicine, Seattle, WA

Production and reactions of oxidants produced by myeloperoxidase
Christine Winterbourn, University of Otago, Christchurch, New Zealand

Neutrophil-mediated DNA damage
Lawrence C. Sowers, Loma Linda University, Loma Linda, CA

3:30 p.m.-4:00 p.m.  Break
   Randle Foyer
4:00 p.m.-5:00 p.m. **Minisymposium II**  
*Proffered presentations from selected abstracts*
*Randle Ballroom*

RNA editing changes the lesion specificity for the DNA repair enzyme NEIL1  
Sheila S. David, University of California, Davis, CA

Environmentally induced oxidative stress: TCDD- and benzo[a]pyrene-mediated arachidonic acid metabolism in H358 human lung cells  
Stacy Lynn Gelhaus, University of Pennsylvania, Philadelphia, PA

Inflammation-induced DNA glycation: A potential role in TNF-α-mediated response mechanisms  
John Termini, City of Hope, Duarte, CA

The metabolism and signaling of the lipid peroxidation product 4-HNE  
Gregory P. Tochtrop, Case Western Reserve University, Cleveland, OH

5:00 p.m.-7:00 p.m. **Poster Session A**  
*Manchester Ballroom*

---

**Tuesday, February 1**

7:00 a.m.-8:00 a.m. **Continental Breakfast**  
*Randle Foyer Terrace*

8:00 a.m.-10:00 a.m. **Session 3: Chemical Mediators of Inflammation II**  
*Chairperson: Cynthia J. Burrows, University of Utah, Salt Lake City, UT*
*Randle Ballroom*

Beyond 8-oxoG: Chemistry and biochemistry of hyperoxidized guanine  
Cynthia Burrows

AGES, inflammation, and cancer in diabetes  
John W. Baynes, University of South Carolina, Columbia, SC

Redox regulation of Ras and Rho GTPases  
Sharon Campbell, University of North Carolina, Chapel Hill, NC

Reaction pathways of radicals formed by the oxidation of guanine in DNA by peroxynitrite-derived reactive intermediates and characterization of the end products  
Nicholas E. Geacintov, New York University, New York, NY
10:00 a.m.-10:30 a.m. **Break**

*Randle Foyer*

10:30 a.m.-11:30 a.m. **Minisymposium III**

*Proffered presentations from selected abstracts*

*Randle Ballroom*

- **Nitrogen-oxide-releasing NSAIDs as anticancer agents**
  Katrina M. Miranda, University of Arizona, Tucson, AZ

- **Caged nitric oxide prodrugs for cancer therapy**
  Larry K. Keefer, National Cancer Institute at Frederick, Frederick, MD

- **Organ- and lesion-dependent biases in the spectrum of inflammation-induced DNA damage in colon and liver from *Helicobacter hepaticus*-infected Rag2-deficient mice**
  Aswin Mangerich, Massachusetts Institute of Technology, Cambridge, MA

- **COX-2 inhibitors in PET imaging of inflammation and cancer**
  Jashim Uddin, Vanderbilt University, Nashville, TN

11:30 a.m.-1:30 p.m. **Poster Session B and Lunch**

*Manchester Ballroom*

1:45 p.m.-3:45 p.m. **Session 4: Biomarkers of Inflammation**

*Chairperson: Steven R. Tannenbaum, Massachusetts Institute of Technology, Cambridge, MA*

*Randle Ballroom*

- **Complex biomarker sets for inflammatory bowel disease**
  Steven R. Tannenbaum

- **Cellular responses to inflammation: Dynamic reprogramming of RNA modifications controls selective translation of stress response proteins**
  Peter C. Dedon, Massachusetts Institute of Technology, Cambridge, MA

- **Lipid oxidation and inflammation**
  Ian A. Blair, University of Pennsylvania School of Medicine, Philadelphia, PA

- **Electrophile-protein adducts as triggers for inflammation-related stress responses**
  Daniel C. Liebler, Vanderbilt University, Nashville, TN

3:45 p.m.-4:15 p.m. **Break**

*Randle Foyer*
4:15 p.m.-5:15 p.m.  **Minisymposium IV**  
*Proffered presentations from selected abstracts*  
*Randle Ballroom*

**A novel mPGES-1 inhibitor with antitumor activity**  
Hui-Hua Chang, University of Arizona, Tucson, AZ

**In vivo imaging of cancer therapy with glucocorticoid-loaded nanoparticles in an experimental model**  
Anita Gianella, Mount Sinai School of Medicine, New York, NY

**Novel celecoxib derivatives that inhibit growth in MCF-7 human breast cancer cell line**  
Leyte L. Winfield, Spelman College, Atlanta, GA

**Design of second-generation silicon derivatives of indomethacin as inhibitors of inflammation and tumor growth: Iterative chemical design in pursuit of optimal bioactivity**  
Uzma I. Zakai, University of Wisconsin, Madison, WI

---

**Wednesday, February 2**

7:00 a.m.-8:00 a.m.  **Continental Breakfast**  
*Randle Foyer Terrace*

8:00 a.m.-10:00 a.m.  **Session 5: Systems Biology of Inflammation**  
*Chairperson: Forest M. White, Massachusetts Institute of Technology, Cambridge, MA*  
*Randle Ballroom*

**Biological insight from quantitative analysis of tyrosine kinase signaling networks**  
Forest White

**Inflammation in human prostate carcinogenesis: An etiological factor triggering somatic epigenome defects in prostate cancer**  
William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

**Systematic functional genomics and cancer**  
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

**Role of nuclear receptors in carcinogenesis**  
Frank J. Gonzalez, National Cancer Institute, Bethesda, MD
10:00 a.m.-10:30 a.m.  Break
   Randle Foyer

10:30 a.m.-12:30 p.m.  Session 6: Chemoprevention and Drug Development
   Chairperson: Lawrence J. Marnett, Vanderbilt University Medical Center, Nashville, TN
   Randle Ballroom

   Substrate-selective inhibition of endocannabinoid oxygenation by cyclooxygenase-2
   Lawrence J. Marnett

   Natural products as leads for cancer therapy: Triptolide and phenanthropiperidines
   Gunda I. Georg, University of Minnesota College of Pharmacy, Minneapolis, MN

   Development of ipilimumab: Lessons learned
   Ramy Ibrahim, Bristol-Myers Squibb Co., Wallingford, CT

   Restoring the immune response to cancers by inhibition of indoleamine 2,3-dioxygenase (IDO)
   Andrew P. Combs, Incyte, Corporation, Kennett Square, PA

12:30 p.m.  Departure